Results for tag: "Wet Macular Degeneration Drug"

The Wet Macular Degeneration Drug market is a subset of the Optical Disorders Drugs market. Wet Macular Degeneration (WMD) is a degenerative eye condition that causes vision loss due to the growth of abnormal blood vessels in the macula, the part of the eye responsible for central vision. WMD drugs are used to slow the progression of the disease and improve vision. These drugs are typically administered via intravitreal injections, which are injections directly into the eye. The WMD Drug market is highly competitive, with a number of companies offering treatments. These include Regeneron Pharmaceuticals, Novartis, Allergan, and Roche. Other companies such as Genentech, Ophthotech, and Santen Pharmaceuticals are also active in the market. Show Less Read more